Lunai Bioworks Inc. current report, 21 May 2024

Business Context and Reporting Period

This Form 8-K Current Report was filed by Renovaro Inc. (trading symbol: RENB) on May 21, 2024. The report addresses corporate governance updates rather than financial performance. The registrant is incorporated in Delaware and maintains its principal executive offices in Los Angeles, California.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to legal and administrative amendments and does not contain financial statements or operational metrics.

Material Changes

On May 21, 2024, the Board of Directors approved an amendment and restatement of the Company's Bylaws. The primary material changes include:

  • Updating the Company's name to "Renovaro Inc." within the Bylaws.
  • Updating the titles of various corporate officers referenced throughout the document.

Guidance, Outlook, and Risks

The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks, contingencies, or unusual items were disclosed in this report. The document serves solely to notify the market of the Bylaw amendments.

Key Facts for Investor Verification

  • Verify the effective date of the Amended and Restated Bylaws (May 21, 2024).
  • Confirm the updated corporate officer titles as reflected in the new Bylaws.
  • Note that the filing was signed by Simon Tarsh, Interim Chief Financial Officer, on May 24, 2024.
  • Review Exhibit 3.1 attached to the filing for the full text of the Amended and Restated Bylaws.